QuidelOrtho reports preliminary Q3 2022 revenue $782-785M; COVID revenue ~$171M

QuidelOrtho Corp

2022-Q3 EPS reported $9.56 revenue$2,399,500,000

Total revenue expected $782M-$785M; non-COVID product revenue $611M-$614M.
COVID-19 product revenue ~$171M, including unanticipated government order and strong retail demand.
Strong performance in Transfusion Medicine and Sofia platform; Labs challenged by China and supply chain.
Full Q3 2022 financial results to be reported on November 2, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.